Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a ...
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...